Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 99

Similar articles for PubMed (Select 16007089)

1.

Distinct epigenetic changes in the stromal cells of breast cancers.

Hu M, Yao J, Cai L, Bachman KE, van den Brûle F, Velculescu V, Polyak K.

Nat Genet. 2005 Aug;37(8):899-905. Epub 2005 Jul 10.

PMID:
16007089
2.

Good neighbors.

Rusk N.

Nat Methods. 2005 Sep;2(9):638-9.

PMID:
16184662
3.

Epigenetic mapping and functional analysis in a breast cancer metastasis model using whole-genome promoter tiling microarrays.

Rodenhiser DI, Andrews J, Kennette W, Sadikovic B, Mendlowitz A, Tuck AB, Chambers AF.

Breast Cancer Res. 2008;10(4):R62. doi: 10.1186/bcr2121. Epub 2008 Jul 18.

4.

Methylation of homeobox genes is a frequent and early epigenetic event in breast cancer.

Tommasi S, Karm DL, Wu X, Yen Y, Pfeifer GP.

Breast Cancer Res. 2009;11(1):R14. doi: 10.1186/bcr2233. Epub 2009 Feb 27.

5.

Identification of alterations in DNA copy number in host stromal cells during tumor progression.

Pelham RJ, Rodgers L, Hall I, Lucito R, Nguyen KC, Navin N, Hicks J, Mu D, Powers S, Wigler M, Botstein D.

Proc Natl Acad Sci U S A. 2006 Dec 26;103(52):19848-53. Epub 2006 Dec 13.

7.

The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.

Hildenbrand R, Schaaf A.

Int J Oncol. 2009 Jan;34(1):15-23.

PMID:
19082473
8.

Epigenetic profiling of multidrug-resistant human MCF-7 breast adenocarcinoma cells reveals novel hyper- and hypomethylated targets.

Chekhun VF, Lukyanova NY, Kovalchuk O, Tryndyak VP, Pogribny IP.

Mol Cancer Ther. 2007 Mar;6(3):1089-98.

9.

Identification of novel high-frequency DNA methylation changes in breast cancer.

Ordway JM, Budiman MA, Korshunova Y, Maloney RK, Bedell JA, Citek RW, Bacher B, Peterson S, Rohlfing T, Hall J, Brown R, Lakey N, Doerge RW, Martienssen RA, Leon J, McPherson JD, Jeddeloh JA.

PLoS One. 2007 Dec 19;2(12):e1314.

10.

Epigenetic silencing of the tumor suppressor cystatin M occurs during breast cancer progression.

Ai L, Kim WJ, Kim TY, Fields CR, Massoll NA, Robertson KD, Brown KD.

Cancer Res. 2006 Aug 15;66(16):7899-909.

11.
12.

Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.

Sigalotti L, Fratta E, Coral S, Cortini E, Covre A, Nicolay HJ, Anzalone L, Pezzani L, Di Giacomo AM, Fonsatti E, Colizzi F, Altomonte M, Calabrò L, Maio M.

J Cell Physiol. 2007 Aug;212(2):330-44. Review.

PMID:
17458893
13.

Breaking down barriers: the importance of the stromal microenvironment in acquiring invasiveness in young women's breast cancer.

Schedin P, Borges V.

Breast Cancer Res. 2009;11(2):102. doi: 10.1186/bcr2235. Epub 2009 Mar 26.

14.

Promoter hypermethylation of the SFRP2 gene is a high-frequent alteration and tumor-specific epigenetic marker in human breast cancer.

Veeck J, Noetzel E, Bektas N, Jost E, Hartmann A, Knüchel R, Dahl E.

Mol Cancer. 2008 Nov 6;7:83. doi: 10.1186/1476-4598-7-83.

15.

Pattern of expression of genes linked to epigenetic silencing in human breast cancer.

Munot K, Bell SM, Lane S, Horgan K, Hanby AM, Speirs V.

Hum Pathol. 2006 Aug;37(8):989-99.

PMID:
16867861
16.

Unmasking of epigenetically silenced genes reveals DNA promoter methylation and reduced expression of PTCH in breast cancer.

Wolf I, Bose S, Desmond JC, Lin BT, Williamson EA, Karlan BY, Koeffler HP.

Breast Cancer Res Treat. 2007 Oct;105(2):139-55. Epub 2007 Feb 13.

PMID:
17295047
17.

Combined total genome loss of heterozygosity scan of breast cancer stroma and epithelium reveals multiplicity of stromal targets.

Fukino K, Shen L, Matsumoto S, Morrison CD, Mutter GL, Eng C.

Cancer Res. 2004 Oct 15;64(20):7231-6.

18.

Epigenetic silencing in non-neoplastic epithelia identifies E-cadherin (CDH1) as a target for chemoprevention of lobular neoplasia.

Zou D, Yoon HS, Perez D, Weeks RJ, Guilford P, Humar B.

J Pathol. 2009 Jun;218(2):265-72. doi: 10.1002/path.2541.

PMID:
19294736
19.

Methylation of estrogen receptor beta promoter correlates with loss of ER-beta expression in mammary carcinoma and is an early indication marker in premalignant lesions.

Rody A, Holtrich U, Solbach C, Kourtis K, von Minckwitz G, Engels K, Kissler S, Gätje R, Karn T, Kaufmann M.

Endocr Relat Cancer. 2005 Dec;12(4):903-16.

20.

Molecular signatures suggest a major role for stromal cells in development of invasive breast cancer.

Casey T, Bond J, Tighe S, Hunter T, Lintault L, Patel O, Eneman J, Crocker A, White J, Tessitore J, Stanley M, Harlow S, Weaver D, Muss H, Plaut K.

Breast Cancer Res Treat. 2009 Mar;114(1):47-62. doi: 10.1007/s10549-008-9982-8. Epub 2008 Mar 29.

PMID:
18373191
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk